Cargando…

How to Optimize the Administration of Low-Dose Non-vitamin K Antagonist Oral Anticoagulants in Everyday Practice?

Detalles Bibliográficos
Autor principal:	Undas, Anetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Turkish Society of Cardiology 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682590/ https://www.ncbi.nlm.nih.gov/pubmed/35949132 http://dx.doi.org/10.5152/AnatolJCardiol.2022.2190

Ejemplares similares

Practical considerations on non-vitamin K oral anticoagulants in patients with high body weight
por: Undas, Anetta
Publicado: (2016)

Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
por: Undas, Anetta, et al.
Publicado: (2020)

Reply to Letter to the Editor: “How to Optimize Administration of Low-Dose NOACs in Everyday Practice?”
por: Li, Ze, et al.
Publicado: (2022)

Anticoagulation in Real-Life Patients with Atrial Fibrillation: Impact of Renal Disease
por: Undas, Anetta
Publicado: (2023)

Adverse outcomes in anticoagulated patients undergoing percutaneous left atrial appendage ligation
por: Undas, Anetta
Publicado: (2020)

Off‐target effects of oral anticoagulants – vascular effects of vitamin K antagonist and non‐vitamin K antagonist oral anticoagulant dabigatran etexilate
por: van Gorp, Rick H., et al.
Publicado: (2021)

Patient Self-Management of Oral Anticoagulation with Vitamin K Antagonists in Everyday Practice: Efficacy and Safety in a Nationwide Long-Term Prospective Cohort Study
por: Nagler, Michael, et al.
Publicado: (2014)

Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions
por: Jacobs, M. S., et al.
Publicado: (2019)

Low-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
por: Lee, Ki Hong, et al.
Publicado: (2023)

Non-Vitamin K Oral Anticoagulants in Stroke Patients: Practical Issues
por: Malhotra, Konark, et al.
Publicado: (2017)

Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation
por: Camm, A. John, et al.
Publicado: (2015)

Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation
por: Zalewski, Jarosław, et al.
Publicado: (2016)

An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants
por: Mujer, Mark Terence P., et al.
Publicado: (2020)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

How to improve the management of a patient with heparin-induced thrombocytopenia?
por: Undas, Anetta
Publicado: (2019)

Comparative effectiveness of oral anticoagulants in everyday practice
por: Camm, A John, et al.
Publicado: (2021)

Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation
por: Farinha, José Maria, et al.
Publicado: (2022)

Geographic Variations in the Quality of Oral Anticoagulation With Vitamin K Antagonists in the Era of New Anticoagulants
por: Fauchier, Laurent, et al.
Publicado: (2013)

Gastrointestinal bleeding during anticoagulation with direct oral anticoagulants compared to vitamin K antagonists
por: Dongre, Kanchan, et al.
Publicado: (2022)

Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: clinical outcomes in a single centre cohort after long-term follow-up
por: Corrochano, M., et al.
Publicado: (2020)

Oral Anticoagulants after Heart Transplantation—Comparison between Vitamin K Antagonists and Direct Oral Anticoagulants
por: Darche, Fabrice F., et al.
Publicado: (2023)

Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting
por: Dincq, Anne-Sophie, et al.
Publicado: (2014)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with β-Thalassemia
por: Malagù, Michele, et al.
Publicado: (2023)

Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants
por: Cullell, Natalia, et al.
Publicado: (2018)

Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease: Practical Issues
por: Matusik, Paweł T., et al.
Publicado: (2022)

Safety of off‐label dose reduction of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
por: van den Dries, Carline J., et al.
Publicado: (2022)

Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants
por: Faraoni, David, et al.
Publicado: (2015)

Impact of Non-vitamin K Antagonist Oral Anticoagulant Withdrawal on Stroke Outcomes
por: Park, Joong Hyun, et al.
Publicado: (2018)

Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding
por: Gremmel, Thomas, et al.
Publicado: (2018)

Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease
por: Fanaroff, Alexander C, et al.
Publicado: (2022)

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis
por: Santarpia, Giuseppe, et al.
Publicado: (2015)

Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral Anticoagulants
por: Kumano, Osamu, et al.
Publicado: (2021)

Safety and effectiveness of anticoagulation with non-vitamin K antagonist oral anticoagulants and warfarin in patients on tuberculosis treatment
por: Lee, Hyun-Jung, et al.
Publicado: (2023)

Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends
por: Shiyovich, Arthur, et al.
Publicado: (2021)

Implementation of non-vitamin K antagonist oral anticoagulants in daily practice: the need for comprehensive education for professionals and patients
por: Heidbuchel, Hein, et al.
Publicado: (2015)

Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK
por: García Rodríguez, Luis Alberto, et al.
Publicado: (2019)

Starting dose and dose adjustment of non-vitamin K antagonist oral anticoagulation agents in a nationwide cohort of patients with atrial fibrillation
por: Gozzo, L., et al.
Publicado: (2021)

Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism
por: Goldstein, Patrick, et al.
Publicado: (2013)

Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulants
por: Patel, Raj
Publicado: (2016)

Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus
por: Iqbal, Hansa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gqf7g2d9r598rksre69ka5t08v